Pfizer ($PFE) CEO Ian Read (photo) told the Financial Times that he hopes to divest the company's animal health and nutrition units by June 13, gaining cash to finance new bolt-on acquisitions and return money to shareholders. Report
For innovative pharmaceutical companies, opportunities for new pharmaceutical products exist within the products, patents, technologies and intellectual properties they already own or control. For these companies, and also for generic companies that are looking for alternative revenue sources to offset losses caused by the generic cliff, the 505(b)(2) pathway offers great potential. Learn more here.
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 100,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!